Injectable biodegradable hydrogels for localized radiotherapy
undisclosedplatform · medium · Thu Oct 01 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Deliver and retain radioisotopes locally for radiotherapy, including filling surgical cavities and producing more homogeneous radiation.
Liquid or semi-solid injectable biodegradable radioactive hydrogel for localized radioisotope delivery.
Patent application WO2015149070A1 was published on 2015-10-01 and lists Washington University in St. Louis/WUSTL among assignees.
Diagnosis-to-treatment interval prognostic research in follicular lymphoma
exploratorybiomarker · high
Evaluate diagnosis-to-treatment interval as a prognostic marker for outcomes in follicular lymphoma treated with immunochemotherapy.
International discovery and validation cohort analysis assessing diagnosis-to-treatment interval beyond established prognostic indices.
2026 Blood publication reports validation of short diagnosis-to-treatment interval as an independent predictor of inferior outcomes.
Short diagnosis-to-treatment interval independently predicted inferior outcomes and may inform risk stratification, clinical trial design, and interpretation.
Gut microbiota translocation and dissemination in health
exploratoryresearch program · medium
Assess whether translocation and dissemination of select live gut microbes can be beneficial or purposeful in health, disease settings, and early life.
Review and synthesis of evidence on gut barrier biology, microbial translocation, dissemination, and host effects.
2026 publication summarizing recent studies suggesting physiologic translocation of select live gut microbes in early life may confer beneficial host effects.
The review argues that microbial translocation is not always pathological and may foster beneficial outcomes in specific contexts, especially early life.
Obesity as a modifiable risk factor in chronic kidney disease
exploratoryresearch program · medium
Characterize obesity and metabolic syndrome as modifiable contributors to chronic kidney disease progression and cardiorenal complications.
Review of pathophysiology, CKD risk phenotypes, and therapeutic strategies including SGLT2 inhibitors, GLP-1 receptor agonists, finerenone, and renin-angiotensin-aldosterone system blockade.
2026 review highlights multitargeted therapeutic strategies for patients with obesity and/or metabolic syndrome and chronic kidney disease.
Integrated multidisciplinary management and multitargeted therapies are described as promising approaches to alter CKD progression and improve outcomes.
Semaglutide and neovascular age-related macular degeneration risk study
exploratoryresearch program · high
Investigate whether semaglutide exposure is associated with neovascular age-related macular degeneration among adults with type 2 diabetes.
Retrospective OHDSI network study across 12 databases using active-comparator cohort design, propensity score-adjusted Cox models, self-controlled case-series analysis, conditional Poisson regression, and random-effects meta-analysis.
Publication reports analysis of 227,971 new semaglutide users during the 2017-12-01 to 2024-12-31 study period.
No differences were detected in neovascular age-related macular degeneration risk associated with semaglutide use among adults with type 2 diabetes.
